Côd QR

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma

Proteasome inhibitors (PIs) are central to multiple myeloma (MM) therapy; however, resistance remains a major clinical challenge, particularly in relapsed/refractory disease. To identify functional mediators of carfilzomib (CFZ) resistance, we performed complementary gain-of-function CRISPR activati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: María Labrador, Sara Cozzubbo, Mariangela Porro, Michela Cumerlato, Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Benedetta Donati, Veronica Manicardi, Domenica Ronchetti, Mattia D’Agostino, Alessandra Larocca, Francesca Gay, Benedetto Bruno, Alessia Ciarrocchi, Andrew Chatr-Aryamontri, Antonino Neri, Eugenio Morelli, Roberto Piva
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2026-05-01
Cyfres:Cells
Pynciau:
MDM2
multiple myeloma
proteasome inhibitors
<i>TP53</i>
drug resistance
synthetic lethality
Mynediad Ar-lein:https://www.mdpi.com/2073-4409/15/9/831
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg